Retinopathy Of Prematurity - Pipeline Review, H2 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 24, 2018--The “Retinopathy Of Prematurity - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Retinopathy Of Prematurity - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Retinopathy Of Prematurity (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 7 respectively.
Retinopathy Of Prematurity (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Report Coverage Retinopathy Of Prematurity - Overview Retinopathy Of Prematurity - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Retinopathy Of Prematurity - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Retinopathy Of Prematurity - Companies Involved in Therapeutics Development D. Western Therapeutics Institute Inc F. Hoffmann-La Roche Ltd Insmed Inc Protheragen Inc Recordati SpA For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3r9782/retinopathy_of?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005356/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Optical Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/24/2018 04:55 AM/DISC: 09/24/2018 04:55 AM